Centessa Pharmaceuticals’ SerpinPC Gains Orphan Drug Designation

The FDA has given Centessa Pharmaceuticals’ SerpinPC Orphan Drug designation for the treatment of patients with hemophilia B.

SerpinPC is a biological drug candidate based on the serpin family of proteins. It’s designed to allow more thrombin to be generated by inhibiting activated protein C. The aim is to provide a rebalance of coagulation, said the company.

Centessa plans to make SerpinPC a subcutaneous option to prevent and reduce bleeds without the risk of thrombosis in patients with hemophilia B.

The company said it will initiate registrational studies for SerpinPC later this year.